Literature DB >> 1545259

The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers.

S A Grossman1, C Reinhard, O M Colvin, M Chasin, R Brundrett, R J Tamargo, H Brem.   

Abstract

The local concentration and distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) within normal brain tissue were studied following surgical implantation of biodegradable polymer containing BCNU in New Zealand White rabbits. Cylindrical discs of poly(bis(p-carboxyphenoxy)-propane:sebacic acid) copolymer in a 20:80 formulation were made containing [3H]-inulin or [3H]-BCNU labeled in the methylene hydrogens of the chloroethyl groups. These were implanted in the brains of 56 New Zealand White rabbits. The animals were sacrificed 3, 7, 14, or 21 days later and the brains were rapidly removed, frozen, and prepared for quantitative autoradiography. Autoradiographs from coronal sections bisecting the polymer were analyzed to determine both the proportion of the brain section exposed to the tracer and the local drug concentrations as a function of distance from the polymer. Tritiated BCNU was also injected directly into the brains of eight additional rabbits, and local brain concentrations were studied over time. The results of this study demonstrate that approximately 50% of the area of the brain sections was exposed to radiolabeled compound 3 days after BCNU-polymer implantation, 15% at 7 days, and less than 10% at 14 and 21 days. Polymer discs containing 600 micrograms BCNU generated 6 mM concentrations of BCNU in brain tissue 10 mm from the polymer at 3 and 7 days. Pharmacological studies demonstrated that approximately 25% of the tritium label was associated with intact BCNU 3 days following polymer implantation. Radiolabeled inulin delivered by polymer remained dispersed throughout the ipsilateral hemisphere for 14 days. Direct injection of [3H]-BCNU into brain parenchyma resulted in widely distributed tracer at 1 and 3 hours with rapid disappearance thereafter. It is concluded that local delivery of BCNU to brain tissue with this polymeric drug delivery system results in sustained high local concentrations of BCNU which may be of value in the treatment of patients with brain tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1545259     DOI: 10.3171/jns.1992.76.4.0640

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  55 in total

1.  Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors.

Authors:  A J Domb; Z H Israel; O Elmalak; D Teomim; A Bentolila
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

2.  Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.

Authors:  Alicia M Mihaliak; Candace A Gilbert; Li Li; Marie-Claire Daou; Richard P Moser; Andrew Reeves; Brent H Cochran; Alonzo H Ross
Journal:  Cancer Lett       Date:  2010-10-28       Impact factor: 8.679

Review 3.  Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.

Authors:  Iason T Papademetriou; Tyrone Porter
Journal:  Ther Deliv       Date:  2015-08-25

4.  Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.

Authors:  Stephan Ulmer; Klara Spalek; Arya Nabavi; Susan Schultka; H Maximillian Mehdorn; Santosh Kesari; Lutz Dörner
Journal:  Neuro Oncol       Date:  2012-02-08       Impact factor: 12.300

Review 5.  Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience.

Authors:  H Christopher Lawson; Prakash Sampath; Eileen Bohan; Michael C Park; Namath Hussain; Alessandro Olivi; Jon Weingart; Lawrence Kleinberg; Henry Brem
Journal:  J Neurooncol       Date:  2006-12-14       Impact factor: 4.130

Review 6.  Polymeric drug delivery for the treatment of glioblastoma.

Authors:  Scott D Wait; Roshan S Prabhu; Stuart H Burri; Tyler G Atkins; Anthony L Asher
Journal:  Neuro Oncol       Date:  2015-03       Impact factor: 12.300

7.  BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.

Authors:  Stuart H Burri; Roshan S Prabhu; Ashley L Sumrall; Wendy Brick; Brian D Blaker; Brent E Heideman; Peggy Boltes; Renee Kelly; James T Symanowski; Walter F Wiggins; Lynn Ashby; H James Norton; Kevin Judy; Anthony L Asher
Journal:  J Neurooncol       Date:  2015-05-07       Impact factor: 4.130

8.  Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.

Authors:  James L Frazier; Paul P Wang; Daniel Case; Betty M Tyler; Gustavo Pradilla; Jon D Weingart; Henry Brem
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

9.  Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.

Authors:  Jennifer A Quinn; Sara Xiaoyin Jiang; James Carter; David A Reardon; Annick Desjardins; James J Vredenburgh; Jeremy N Rich; Sridharan Gururangan; Allan H Friedman; Darell D Bigner; John H Sampson; Roger E McLendon; James E Herndon; Stevie Threatt; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 10.  Pharmacokinetics of the carmustine implant.

Authors:  Alison B Fleming; W Mark Saltzman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.